(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688799 · · 14 pages · Chinese
Summary by 6ix AI
The report indicates a significant decline in revenue and profit compared to the same period last year, with specific figures provided for total revenue and net profit attributable to shareholders. Additionally, the report outlines various operational updates, including product registrations and ongoing clinical trials for new drugs. The financial statements included in the report have not been audited, and the company has provided assurances regarding the accuracy and completeness of the information presented.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hunan Warrant Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Warrant Pharmaceutical
- (688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Receipt of the Approval Notice for the Marketing Application for an API
- (688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Obtaining of the Approval Notice for Its API Marketing Application
- (688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate
Follow Hunan Warrant Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Warrant Pharmaceutical